A study of MGD014 for the treatment of HIV infections
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2017
At a glance
- Drugs MGD 014 (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 08 Nov 2017 According to a company media release, MacroGenics' IND submission for MGD014 has been cleared by the US FDA and the Company anticipates that a first patient will be dosed in early 2018.
- 05 Sep 2017 According to a MacroGenics media release, the company has submitted an IND for MGD014.
- 11 May 2016 New trial record